[Immunomodulator therapy for maintenance of remission in Crohn's disease].
Iwao
Yasushi
Y
Center for Conprehensive and Advanced Medicine, Keio University School of Medicine.
D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects* / Q000493:pharmacokinetics; D007958:Leukocyte Count; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008780:Methyltransferases / Q000235:genetics / Q000502:physiology; D008991:Monitoring, Physiologic; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011755:Pyrophosphatases / Q000235:genetics / Q000502:physiology; D012074:Remission Induction; D000097630:Inosine Triphosphatase
D001379:Azathioprine; D007155:Immunologic Factors; D015122:Mercaptopurine; D008780:Methyltransferases; D011755:Pyrophosphatases; C022745:thiopurine methyltransferase; C511829:ITPA protein, human; D000097630:Inosine Triphosphatase